We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00225186
Previous Study | Return to List | Next Study

Safety and Efficacy of SH T00660AA in Treatment of Endometriosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00225186
Recruitment Status : Completed
First Posted : September 23, 2005
Last Update Posted : January 9, 2014
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to demonstrate safety and efficacy of SH T00660AA for the treatment of endometriosis

Condition or disease Intervention/treatment Phase
Endometriosis Drug: Visanne (SH T00660AA , BAY86-5258) Phase 3

Detailed Description:
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 168 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Open, One-arm Study to Investigate the Safety and Efficacy of Daily Oral Administration of T00660AA for the Treatment of Endometriosis Over 52 Weeks (Follow-up to Study 307041)
Study Start Date : July 2004
Actual Primary Completion Date : March 2008
Actual Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endometriosis Safety

Arm Intervention/treatment
Experimental: Arm 1 Drug: Visanne (SH T00660AA , BAY86-5258)
Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients

Primary Outcome Measures :
  1. Safety assessment of the drug [ Time Frame: 12-18 months ]

Secondary Outcome Measures :
  1. Efficacy (reduction of pelvic pain) [ Time Frame: 12-18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female patients with endometriosis-associated pelvic pain

Exclusion Criteria:

  • Pregnant or lactating women
  • History or suspicion of hormone dependent tumor
  • Therapy resistant endometriosis or need for primary surgical treatment
  • Any other conditions which forbid the participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00225186

Layout table for location information
Heidelberg, Baden-Württemberg, Germany, 69115
Tuebingen, Baden-Württemberg, Germany, 72076
Krumbach, Bayern, Germany, 86381
München, Bayern, Germany, 81241
Nuernberg, Bayern, Germany, 90419
Giessen, Hessen, Germany, 35392
Mühlheim, Hessen, Germany, 63165
Aachen, Nordrhein-Westfalen, Germany, 52074
Gevelsberg, Nordrhein-Westfalen, Germany, 58285
Münster, Nordrhein-Westfalen, Germany, 48129
Kalbe, Sachsen-Anhalt, Germany, 39624
Dippoldiswalde, Sachsen, Germany, 01744
Leipzig, Sachsen, Germany, 04103
Marienberg, Sachsen, Germany, 09496
Weißig, Sachsen, Germany, 01474
Lübeck, Schleswig-Holstein, Germany, 23538
Greifswald, Germany, 17487
Brescia, Italy, 25123
Cagliari, Italy, 09042
Napoli, Italy, 80138
Roma, Italy, 00165
Torino, Italy, 10127
Chernivtsi, Ukraine, 58017
Kiev, Ukraine, 01030
Kiev, Ukraine, 04050
Kiev, Ukraine, 04107
Kiev, Ukraine, 04210
Vinnitsa, Ukraine, 21000
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Publications of Results:
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00225186    
Other Study ID Numbers: 91234
307059 ( Other Identifier: company internal )
First Posted: September 23, 2005    Key Record Dates
Last Update Posted: January 9, 2014
Last Verified: January 2014
Additional relevant MeSH terms:
Layout table for MeSH terms